(IBRX) Immunitybio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 8.086m USD | Total Return: 169.4% in 12m
Avg Turnover: 89.2M
Qual. Beats: 0
Rev. Trend: 95.6%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Share dilution 20.4% YoY
Interest Coverage Ratio -1.9 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies to treat cancer and infectious diseases. Its proprietary platforms utilize cytokine fusion proteins, DNA vaccines, and cell therapies to stimulate the patients immune system. The company’s lead product, Anktiva, recently received FDA approval for use in combination with bacillus calmette-guérin (BCG) for specific types of non-muscle invasive bladder cancer.
The biotechnology sector is characterized by high research and development (R&D) intensity and a long regulatory approval cycle often spanning over a decade. ImmunityBio operates on a collaborative business model, maintaining strategic partnerships with institutions such as the National Cancer Institute and the Serum Institute of India to scale its clinical and manufacturing capabilities.
Investors can further analyze the companys financial health and valuation metrics on ValueRay. ImmunityBio remains focused on expanding its therapeutic pipeline into liquid and solid tumor treatments through ongoing clinical trials.
- Anktiva commercial launch and adoption rates in bladder cancer market
- FDA regulatory decisions on expanded indications for solid tumor therapies
- Manufacturing scalability and supply chain stability for biologic product candidates
- High cash burn rate necessitates future capital raises or strategic partnerships
- Clinical trial data readouts for cytokine fusion proteins and cell therapies
| Net Income: -854.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.25 > 0.02 and ΔFCF/TA -5.24 > 1.0 |
| NWC/Revenue: 273.1% < 20% (prev 192.0%; Δ 81.06% < -1%) |
| CFO/TA -0.46 > 3% & CFO -294.4m > Net Income -854.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.03b) vs 12m ago 20.36% < -2% |
| Gross Margin: 93.79% > 18% (prev 0.72%; Δ 9.31k% > 0.5%) |
| Asset Turnover: 29.67% > 50% (prev 10.28%; Δ 19.39% > 0%) |
| Interest Coverage Ratio: -1.85 > 6 (EBITDA TTM -191.8m / Interest Expense TTM 112.1m) |
| A: 0.60 (Total Current Assets 453.0m - Total Current Liabilities 68.0m) / Total Assets 646.6m |
| B: -6.74 (Retained Earnings -4.36b / Total Assets 646.6m) |
| C: -0.44 (EBIT TTM -207.8m / Avg Total Assets 475.2m) |
| D: -2.86 (Book Value of Equity -4.33b / Total Liabilities 1.52b) |
| Altman-Z'' = -24.01 = D |
| DSRI: 0.55 (Receivables 43.3m/17.5m, Revenue 141.0m/31.2m) |
| GMI: 0.77 (GM 93.79% / 71.96%) |
| AQI: 0.81 (AQ_t 0.07 / AQ_t-1 0.09) |
| SGI: 4.52 (Revenue 141.0m / 31.2m) |
| TATA: -0.87 (NI -854.5m - CFO -294.4m) / TA 646.6m) |
| Beneish M = -2.09 (Cap -4..+1) = BB |
As of May 24, 2026, the stock is trading at USD 7.74 with a total of 21,371,500 shares traded.
Over the past week, the price has changed by -9.41%,
over one month by -10.53%,
over three months by -26.55% and
over the past year by +169.40%.
Immunitybio has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy IBRX.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.3 | 97% |
Revenue TTM = 141.0m USD
EBIT TTM = -207.8m USD
EBITDA TTM = -191.8m USD
Long Term Debt = 678.4m USD (from longTermDebt, last quarter)
Short Term Debt = 8.56m USD (from shortTermDebt, last quarter)
Debt = 1.17b USD (from shortLongTermDebtTotal, last quarter) + Leases 40.8m
Net Debt = 910.8m USD (calculated: Debt 1.17b - CCE 254.6m)
Enterprise Value = 9.00b USD (8.09b + Debt 1.17b - CCE 254.6m)
Interest Coverage Ratio = -1.85 (Ebit TTM -207.8m / Interest Expense TTM 112.1m)
EV/FCF = -11.14x (Enterprise Value 9.00b / FCF TTM -807.5m)
FCF Yield = -8.98% (FCF TTM -807.5m / Enterprise Value 9.00b)
FCF Margin = -572.8% (FCF TTM -807.5m / Revenue TTM 141.0m)
Net Margin = -606.2% (Net Income TTM -854.5m / Revenue TTM 141.0m)
Gross Margin = 93.79% ((Revenue TTM 141.0m - Cost of Revenue TTM 8.75m) / Revenue TTM)
Gross Margin QoQ = none% (prev 88.91%)
Tobins Q-Ratio = 13.91 (Enterprise Value 9.00b / Total Assets 646.6m)
Interest Expense / Debt = 9.62% (Interest Expense 112.1m / Debt 1.17b)
Taxrate = 21.0% (US default 21%)
NOPAT = -164.2m (EBIT -207.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.72 (Total Current Assets 453.0m / Total Current Liabilities 79.1m)
Debt / Equity = -1.34 (negative equity) (Debt 1.17b / totalStockholderEquity, last quarter -870.0m)
Debt / EBITDA = -4.75 (negative EBITDA) (Net Debt 910.8m / EBITDA -191.8m)
Debt / FCF = -1.13 (negative FCF - burning cash) (Net Debt 910.8m / FCF TTM -807.5m)
Total Stockholder Equity = -616.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -179.8% (out of range, set to none)
RoE = -22.83% (Net Income TTM -854.5m / Total Stockholder Equity 3.74b)
RoCE = -4.70% (EBIT -207.8m / Capital Employed (Equity 3.74b + L.T.Debt 678.4m))
RoIC = -37.32% (negative operating profit) (NOPAT -164.2m / Invested Capital 439.9m)
WACC = 12.33% (E(8.09b)/V(9.25b) * Re(13.01%) + D(1.17b)/V(9.25b) * Rd(9.62%) * (1-Tc(0.21)))
Discount Rate = 13.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 27.86%
[DCF] Fair Price = unknown (Cash Flow -807.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.23 | # QB: 0
Revenue Correlation: 95.58 | Revenue CAGR: 1.12k% | SUE: 0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.07 | Chg30d=-10.58% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.07 | Chg30d=-8.33% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=-211.88% | Revisions=+0% | GrowthEPS=-107.9% | GrowthRev=+102.8%
EPS next Year (2027-12-31): EPS=0.10 | Chg30d=N/A | Revisions=-20% | GrowthEPS=+113.3% | GrowthRev=+132.6%
[Analyst] Revisions Ratio: -20%